Renee Rouleau

MARCH 10, 2023

Learn more about the different marketing terms used in skin care and what they really mean. People tend to assume natural fragrances are better than synthetic ones, but I think a lot of this has to do with the increased popularity of “clean” beauty marketing. What is Fragrance? The short answer is no.

Skincare 195

Skincare Irritation Ingredients Sensitive Skin 195

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The company is currently preparing for Phase 2/3 trials with anticipated initiation in 1Q 2025.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. Food and Drug Administration for the treatment of AD and PN.

Dermatitis 36

Dermatitis Hospital Marketing Clinic 36

The Dermatology Digest

FEBRUARY 10, 2025

Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) in the UK and EU for CORDStrom in Recessive Dystrophic Epidermolysis Bullosa (RDEB). This trial showed a favorable benefit-risk profile in support of the intended applications for marketing authorization. INmune Bio, Inc.

Hospital 36

Hospital Sustainability Therapy Marketing 36

The Dermatology Digest

MARCH 3, 2025

approved by the EC, the Company expects to market B-VEC under the registered European trademark, Vyjuvek. The long-term safety and efficacy of B-VEC is further supported by results from the Companys open label extension study completed in the United States as well as real-world experience with B-VEC since launching the United States in 2023.

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

MARCH 5, 2025

This is a great milestone for our team, as we continue to examine the acne market, we believe there is still a high unmet need by patients for an acne product like XYNGARI, says Gerry Proehl, Dermatas Chairman, President, and Chief Executive Officer, in a news release. Food and Drug Administration.

Treatments 36

Treatments Rosacea Pores Office 36

The Dermatology Digest

APRIL 16, 2024

Market Access at Teva, in a news release. Bringing Selarsdi to market in the U.S. The post FDA Green Lights New Stelara Biosimilar appeared first on The Dermatology Digest. says Thomas Rainey, Senior Vice President, U.S. Robert Wessman, Chairman and CEO of Alvotech, adds, “.

Partnerships 74

Partnerships Injections Safety Marketing 74

Texas Dermatology

DECEMBER 24, 2024

To help you maximize your results, Texas Dermatology is sharing the top 3 tips for effective laser hair removal aftercare. At Texas Dermatology we want our patients to achieve the best possible results, which is why we use the Candela GentleMax Pro Plus.

Hair Removal 36

Hair Removal Waxing Moisturization Med Spa 36

The Dermatology Digest

FEBRUARY 14, 2024

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

APRIL 23, 2024

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The BLA for pz-cel was accepted for filing and granted priority review designation by the FDA in November 2023.

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

FEBRUARY 26, 2024

Marketing Authorization Application. About the MIRA trial The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa.

Office 74

Office Clinic Safety Innovations 74

The Dermatology Digest

FEBRUARY 26, 2024

Swierk noted that the research on the safety implications of tattoos is still out. Regulation of tattoo inks on the American market is very recent. The tattoo inks available in the American and European markets differ because the latter is subject to stricter regulations, overseen by the European Chemicals Agency.

Ingredients 74

Ingredients Marketing Safety Dermatology 74

The Beauty Brains

MAY 13, 2019

The Beauty Brains episode 182 – we cover beauty questions about BB glow facials The safety of self tanners Doing you own research and Hard water and your beauty products Beauty Science News Butt Masks Is natural deodorant necessary ? So, with the uncertain safety profile and the limited benefit I’m not sure I can recommend doing this.

Safety 40

Safety Facials Injections Ingredients 40

New Age Spa Institute

DECEMBER 18, 2024

The Clinical Aesthetics Certification is 70 hours of continuing education units (CEU) and ideal for professionals aiming to work in medical spas, dermatology clinics, or with advanced skincare treatments. Licensed estheticians and cosmetologists interested in medspa and advanced modalities.

Medical 52

Medical Esthetics Legal Continuing Education 52

The Dermatology Digest

MARCH 22, 2024

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. Right now, there are many questions about this issue.

Rosacea 64

Rosacea Document Safety Ingredients 64

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. .” The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

DECEMBER 20, 2023

Before Harbor Health, he led product and go-to-market functions for CVS’s kidney care and home business units. Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. is a Professor of Dermatology and Director of Dermatologic Surgery at the University of Minnesota.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

JUNE 14, 2024

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD. ICP-332 achieved multiple efficacy endpoints in the China Phase II study of patients with moderate-to-severe AD and demonstrated an “outstanding” and safety profile.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris. This marks the fourth FDA-approved biosimilar for Stelara. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

JULY 22, 2024

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

FEBRUARY 5, 2024

We are honored to be recognized for the 2024 People’s Choice Award by Octane’s esteemed judges, entrepreneurs and experts in dermatology and plastic surgery,” says Dina El-Sherif, MBA, founder and CEO of Trufacial, in a news release (Pictured above).

Dermatology 36

Dermatology Pharmaceutical Technology Sales 36

The Dermatology Digest

FEBRUARY 27, 2024

While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S. We strongly believe that biosimilars are important in addressing inflationary pressures in the healthcare system across all markets, especially in the U.S. Both Alvotech and Teva expect to launch SIMLANDI in the U.S.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

DECEMBER 13, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization for nemolizumab (Nemluvio. The positive CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorization.

Dermatitis 36

Dermatitis Safety Marketing Therapy 36

The Dermatology Digest

APRIL 9, 2025

This tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety. With its Health Canada clearance, Cynosure Lutronic is prioritizing Canada as its first North American launch market. The devices Spider Pattern Tip is designed to reduce skin-edge effects.

Technology 36

Technology Office Surgery Safety 36

The Dermatology Digest

MAY 23, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology, Harvard Medical School, Boston, MA. “In The safety profile of bimekizumab was consistent with safety data seen in previous trials with no new observed safety signals. The primary endpoint in both trials was HiSCR50 at Week 16.

Sustainability 36

Sustainability Safety Clinic Medical 36

The Dermatology Digest

JULY 10, 2024

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

AUGUST 13, 2024

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

The Dermatology Digest

JUNE 10, 2024

Marketing Authorization Application. Two global, randomized, double blind, placebo-controlled trials are planned (IZAR-1 and IZAR-2) to evaluate the efficacy and safety of the nanobody sonelokimab over one year.

Office 36

Office Safety Marketing Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

The approval is based on data from the Phase 3 ECZTRA 6 trial, which evaluated the efficacy and safety of Adbry in 289 pediatric patients aged 12-17 years with moderate-to-severe AD who were candidates for systemic therapy. Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University in Chicago, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

The approval is based on data from the Phase 3 ECZTRA 6 trial, which evaluated the efficacy and safety of Adbry in 289 pediatric patients aged 12-17 years with moderate-to-severe AD who were candidates for systemic therapy. Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University in Chicago, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

MARCH 11, 2024

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. No new safety signals were observed in this trial. The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

FEBRUARY 9, 2024

There are systemic treatments on the market that have data for atopic dermatitis (AD) on the hands, but chronic hand eczema is defined as hand eczema that lasts for more than three months or relapses twice or more within a year – which applies to several other different kinds of hand eczema as well, not just AD.

Eczema 36

Eczema Marketing Dermatitis Dermatology 36

The Dermatology Digest

FEBRUARY 13, 2024

MediWound Ltd’s EscharEx bested market leader collagenase Santyl ointment in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU). The safety profile and overall incidence of adverse wound reactions were comparable between arms. days for EscharEx vs. 76.0

Safety 36

Safety Marketing Office Clinic 36

The Dermatology Digest

MARCH 20, 2024

Starting at this year’s Miami Open, La Roche-Posay will have a Sun Safety Booth located on the Tennis Oasis, two additional sampling kiosks at key entry points, while also providing sunscreen to players and staff on the grounds. The Miami Open is taking place from March 17 to March 31 at Hard Rock Stadium in Miami Gardens, Florida.

Branding 36

Branding Partnerships Safety Dermatology 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Remember, your health and safety are worth every penny spent on genuine Botox treatments. Counterfeit Botox is not merely ineffective; it’s potentially life-threatening as well.

Office 36

Office Surgery Safety Injections 36

West Lake Dermatology

JANUARY 30, 2024

The market has seen a surge in at-home laser hair removal devices offering users the convenience of performing the treatment in the comfort of their homes. Safety should always be a top priority when considering any form of laser treatment. Professional laser hair removal achieves 95%+ hair removal within 7-9 sessions.

Hair Removal 36

Hair Removal Safety Technology Waxing 36